YMER || ISSN : 0044-0477
http://ymerdigital.com
Nasal drug delivery for Chronic Rhinosinusitis:
An Overview
Archna Gautam*
Research Scholar
archna.gautam909@gmail.com
IIMT UNIVERSITY MEERUT (U.P)
Dr. Divya Pathak
Associate Professor
IIMT UNIVERSITY MEERUT (U.P)
Abstract
Nasal delivery is the logical choice for topical treatment of local diseases in the nose and Paranasal
sinuses such as allergic and non-allergic rhinitis and sinusitis. The nose is also considered an
attractive route for needle-free vaccination and for systemic drug delivery, especially when rapid
absorption and effect are desired. In addition, nasal delivery may help address issues related to
poor bioavailability, slow absorption, drug degradation, and adverse events in the
gastrointestinal tract and avoids the first-pass metabolism in the liver. However, when considering
nasal delivery devices and mechanisms, it is important to keep in mind that the prime purpose of
the nasal airway is to protect the delicate lungs from hazardous exposures, not to serve as a delivery
route for drugs and vaccines. The narrow nasal valve and the complex convoluted nasal geometry
with its dynamic cyclic physiological changes provide efficient filtration and conditioning of the
inspired air, enhance olfaction, and optimize gas exchange and fluid retention during exhalation.
However, the potential hurdles these functional features impose on efficient nasal drug delivery are
often ignored. With this background, the advantages and limitations of existing and emerging nasal
delivery devices and dispersion technologies are reviewed with focus on their clinical
performance. The role and limitations of the in vitro testing in the FDA guidance for nasal spray
pumps and pressurized aerosols (pressurized metered-dose inhalers) with local action are
discussed. Moreover, the predictive value and clinical utility of nasal cast studies and computer
simulations of nasal airflow and deposition with computer fluid dynamics software are briefly
discussed. New and emerging delivery technologies and devices with emphasis on BiDirectional™ delivery,
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:823
YMER || ISSN : 0044-0477
http://ymerdigital.com
Keywords Drug delivery Nasal Device Paranasal sinuses Topical Systemic Vaccine Nasal valve
Particle deposition Clearance
Introduction
Intuitively, the nose offers easy access to a large mucosal surface well suited for drug- and vaccine
delivery. However, factors related to the nasal anatomy, physiology and aerodynamics that can
severely limit this potential, have historically been challenging to address. The most recent FDA
guidance for nasal devices provides detailed guidelines for in vitro testing of the physical
properties such as in vitro reproducibility and accuracy of plume characteristics and dose
uniformity of mechanical liquid spray pumps and pressurized metered-dose inhalers (pMDIs)
for nasal use [1]. The guidance primarily addresses in vitro testing of nasal sprays and pressurized
aerosols for local action. The reference to in vivo performance is limited to the
recommendation of minimizing the fraction of respirable particles below 9 μm in order to avoid
lung inhalation of drugs intended for nasal delivery. Thus, although important as measures
of the quality and reliability of the spray pump and pMDI mechanics, these in vitro tests do
not necessarily predict the in vivo particle deposition, absorption, and clinical response [2].
Furthermore, the guidance offers no or limited guidance on nasal products for systemic
absorption and for alternative dispensing methods like drops, liquid jets, nebulized aerosol,
vapors, and powder formulations. Finally, it does not address aspects and challenges related to
the nasal anatomy and physiology that are highly relevant for the device performance in the
position, need for coordination, and impact of airflow and breathing patterns at delivery.
The mechanical properties of different modes of aerosol generation are already well described
in depth in a previous publication [3]. The anatomy and physiology of the nasal airway has
also recently been summarized in an excellent recent review [4]. The aim of this paper is
to take a step further by reviewing the characteristics of existing and emerging nasal delivery
devices and concepts of aerosol generation from the perspective of achieving the clinical
promise of nasal drug and vaccine delivery. Focus is put on describing how the nasal anatomy
and physiology present substantial obstacles to efficient delivery, but also on how it may be
possible to overcome these hurdles by innovative approaches that permit realization of the
therapeutic potential of nasal drug delivery. Specific attention is given to the particular
challenge of targeted delivery of drugs to the upper narrow parts of the complex nasal passages
housing the middle meatus where the sinuses openings are located, as well as the regions
innervated by the olfactory nerve and branches of the trigeminal nerve considered essential
for efficient “nose-to-brain” (N2B) transport.
Nasal anatomy and physiology influencing drug delivery
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:824
YMER || ISSN : 0044-0477
http://ymerdigital.com
Regulation of nasal airflow
Nasal breathing is vital for most animals and also for human neonates in the first weeks of life. The
nose is the normal and preferred airway during sleep, rest, and mild exercise up to an air volume of
20–30 l/min [5]. It is only when exercise becomes more intense and air exchange demands increase
that oral breathing supplements nasal breathing. The switch from nasal to or nasal breathing in
young adults appears when ventilation is increased to about 35 l/min, about four times resting
ventilation [6]. More than 12,000 l of air pass through the nose every day [5]. The functionality of
the nose is achieved by its complex structure and aerodynamics. Amazingly, the relatively short airpath in the nose accounts for as much as 50–75 % of the total airway resistance during inhalation
[7, 8].
The nasal valve and aerodynamics
The narrow anterior triangular dynamic segment of the nasal anatomy called the nasal valve is the
primary flow-limiting segment, and extends anterior and posterior to the head of the inferior
turbinate approximately 2–3 cm from the nostril opening [9]. This narrow triangular-shaped slit
acts as a dynamic valve to modify the rate and direction of the airflow during respiration
[10, 11]. Anatomical studies de- scribe the static valve dimensions as 0.3–0.4 cm2 on each side,
whereas acoustic rhinometry studies report the functional cross-sectional area perpendicular
to the acoustic pathway to be between 0.5 and 0.6 cm2 on each side, in healthy adults,
with no, or minimal gender differences [11–14]. The flow rate during tidal breathing creates
air velocities at gale force (18 m/s) and can approach the speed of a hurricane (32 m/s) at sniffing
[11, 15]. At nasal flow rates found during rest (up to 15 l/min), the flow regimen is predominantly
laminar throughout the nasal passages. When the rate increases to 25 l/min, local turbulence occurs
down- stream of the nasal valve [10, 11, 15]. The dimensions can expand to increase airflow by
dilator muscular action known as flaring, or artificially by mechanical expansion by internal or
external dilators [16, 17]. During inhalation, Bernoulli forces narrow the valve progressively with
increasing inspiratory flow rate and may even cause complete collapse with vigorous sniffing in
some subjects [5]. During exhalation, the valve acts as a “brake” to maintain a positive
expiratory airway pressure that helps keep the pharyngeal and lower airways open and
increase the duration of the expiratory phase. This “braking” allows more time for gas exchange
in the alveoli and for retention of fluid and heat from the warm saturated expiratory air [4, 17, 18].
In fact, external dilation of narrow noses in obstructive sleep apnea patients had beneficial effects,
whereas dilation of normal noses to “supernor- mal” dimensions had deleterious effects on sleep
parameters [17]. However, in the context of nasal drug delivery, the small dimensions of the nasal
valve, and its triangular shape that narrows further during nasal inhalation, represent important
obstacles for efficient nasal drug delivery.
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:825
YMER || ISSN : 0044-0477
http://ymerdigital.com
The nasal mucosa—filtration and clearance
The region anterior to the valve called the vestibule is lined by non-ciliated squamous epithelium
that in the valve region gradually transitions into ciliated epithelium typical of the ciliated
respiratory epithelium posterior to the valve region [4, 19]. Beyond the nasal valve, the nasal
turbinates divide the nasal cavity into slit-like passages with much larger cross- sectional area and
surface area (Figs. 1, 2 and 3). Here, the predominantly laminar airflow is slowed down to speeds
of 2–3 m/s and disrupted with eddies promoting deposition of particles carried with the air at
and just beyond the valve region [11]. The ciliated respiratory mucosa posterior to the nasal
valve is covered by a protective mucous blanket designed to trap particles and
microorganisms [4, 19].The beating action of cilia moves the mucous blanket towards the
nasopharynx at an average speed of 6 mm/min (3–25 mm/min) [20, 21]. The large surface
area and close contact enables effective filtering and conditioning of the inspired air and retention
of water during exhalation (Figs. 1, 2 and 3). Oral breathing increases the net loss of water by as
much as 42 % compared to nasal breathing [22].
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:826
YMER || ISSN : 0044-0477
http://ymerdigital.com
The optimized during evolution to protect the lower airways from the constant exposure to airborne
pathogens and particles.
Specifically, particles larger than 3–10 μm are efficiently filtered out and trapped by the mucus
blanket [19]. The nose also acts as an efficient “gas mask” removing more that 99 % of watersoluble, tissue-damaging gas like sulfur dioxide [23]. Infective agents are presented to the abundant
nasal immune system both in the mucous blanket, in the mucosa, and in the adjacent organized
lymphatic structures making the nose attractive for vaccine delivery with potential for a
longstanding combination of systemic and mucosal immune responses [24]. The highly
vascularized respiratory mucosa found beyond the valve allows exchange of heat and moisture
with the inspired air within fractions of a second, to transform cold winter air into conditions more
reminiscent of a tropical summer [19].
The nasal cycle
The physiological alternating congestion and decongestion observed in at least 80 % of healthy
humans is called the nasal cycle [5, 25]. The nasal cycle was first described in the rhinological
literature by a German physician in 1895, but was recognized in Yoga literature centuries before
[5]. Healthy individuals are normally unaware of the spontaneous and irregular reciprocal 1–4h cycling of the nasal caliber of the two individual passages, as the total nasal resistance remains
fairly constant [26]. The autonomic cyclic change in airflow resistance is mainly dependent on the
blood content of the submucosal capacitance vessels that constitute the erectile component at
critical sites, notably the nasal valve region. Furthermore, the erectile tissues of the septal and
lateral walls and the turbinates respond to a variety of stimuli including physical and sexual activity
and emotional states that can modify and override the basic cyclic rhythm [4]. The cycle is present
during sleep, but overridden by pressures applied to the lateral body surface during recumbency to
decongest the uppermost/contralateral nasal passage. It has been suggested that this phenomenon
causes a person to turn from one side to the other while sleeping [5, 27]. The cycle is suppressed in
intubated subjects, but restored by resumption of normal nasal breathing [28]. The cycle may also
cause accumulation of nitric oxide (NO) in the congested passage and adjacent sinuses and
contribute to defense against microbes through direct antimicrobial action and enhanced
mucociliary clearance [29]. Measurements have shown that the concentration of NO in the
inspired air is relatively constant due to the increase in NO concentration within the more
congested cavity, which nearly exactly counterbalances the decrease in nasal airflow [30]. In some
patients, as a result of structural deviations and inflammatory mucosal swelling, the nasal cycle may
become clinically evident and cause symptomatic obstruction [19]. Due to the cycle, one of the
nostrils is considerably more congested than the other most of the time, and the vast majority
of the airflow passes through one nostril while the other remains quite narrow Consequently, the
nasal cycle contributes significantly to the dynamics and resistance in the nasal valve region and
must be taken into consideration when the efficiency of nasal drug delivery devices is
considered.
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:827
YMER || ISSN : 0044-0477
http://ymerdigital.com
Nasal and sinus vasculature and lymphatic system
For nasally delivered substances, the site of deposition may influence the extent and route of
absorption along with the target organ distribution. Branches of the ophthalmic and maxillary
arteries supply the mucous membranes covering the sinuses, turbinates, meatuses, and septum,
whereas the superior labial branch of the facial artery supplies the part of the septum in the region
of the vestibule. The turbinates located at the lateral nasal wall are highly vascularized with a
very high blood flow and act as a radiator to the airway. They contain erectile tissues and
arteriovenous anastomoses that allow shunting and pooling related to temperature and water control
and are largely responsible for the mucosal congestion and decongestion in health and disease
[19, 31].
Substances absorbed from the anterior regions are more likely to drain via the jugular veins,
whereas drugs absorbed from the mucosa beyond the nasal valve are more likely to drain via
veins that travel to the sinus cavernous, where the venous blood comes in direct contact with
the walls of the carotid artery. A substance absorbed from the nasal cavity to these veins/venous
sinuses will be outside the blood–brain barrier (BBB), but for substances such as midazolam,
which easily bypass the BBB, this route of local “counter-current transfer” from venous blood
may provide a faster and more direct route to the brain. Studies in rats support that a preferen- tial,
first-pass distribution to the brain through this mechanism after nasal administration may exist for
some, but not all small molecules [32, 33]. The authors suggested that this counter- current
transport takes place in the area of the cavernous sinus– carotid artery complex, which has a similar
structure in rat and man, but the significance of this mechanism for nasally delivered drugs has not
been demonstrated in man [32, 33].
The lymphatic drainage follows a similar pattern as the venous drainage where lymphatic vessels
from the vestibule drain to the external nose to submandibular lymph nodes, whereas the more
posterior parts of the nose and paranasal sinuses drain towards the nasopharynx and internal
deep lymph nodes [4]. In the context of nasal drug delivery, perivascular spaces along the
olfactory and trigeminal nerves acting as lymphatic pathways between the CNS and the nose have
been implicated in the transport of molecules from the nasal cavity to the CNS [34].
Innervation of the nasal mucosa
The nose is also a delicate and advanced sensory organ designed to provide us with the greatest
pleasures, but also to warn and protect us against dangers. An intact sense of smell plays an
important role in both social and sexual interactions and is essential for quality of life. The
sense of smell also greatly contributes to taste sensations [35]. Taste qualities are greatly
refined by odor sensations, and without the rich spectrum of scents, dining and wining and life in
general would become dull [36]. The olfactory nerves enter the nose through the cribriform plate
and extend downwards on the lateral and medial side of the olfactory cleft. Recent biopsy studies
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:828
YMER || ISSN : 0044-0477
http://ymerdigital.com
in healthy adults suggest that the olfactory nerves extend at least 1–2 cm further anterior and
downwards than the 8–10 mm described in most textbooks (see Figs. 1 and 2) [37, 38]. The
density decreases, but olfactory filaments and islets with olfactory epithelium are found in both
the anterior and posterior parts at the middle turbinate. In addition, sensory fibers of both the
ophthalmic and maxillary branches of the trigeminal nerve contribute to olfaction by mediating a
“common chemical sense” [39]. Branches of the ophthalmic branch of the trigeminal nerve provide
sensory innervation to the anterior part of the nose including the vestibule, whereas maxillary
branches inner- vate the posterior part of the nose as well as the regions with olfactory epithelium.
The olfactory and trigeminal nerves mutually interact in a complex manner. The trigeminal
system can modulate the olfactory receptor activity through local peptide release or via reflex
mechanisms designed to minimize the exposure to and effects of potentially noxious substances
[39]. This can occur by alteration of the nasal patency and airflow and through changes in
the properties of the mucous blanket covering the epithelium. Trigeminal input may amplify
odorous sensation through perception of nasal airflow and at the chemosensory level. Interestingly,
an area of increased trigeminal chemosensitivity is found in the anterior part of the nose, mediating
touch, pressure, temperature, and pain [39]. Pain receptors in the nose are not covered by squamous
epithelium, which gives chemical stimuli almost direct ac- cess to the free nerve endings. In
fact, loss of trigeminal sensitivity and function, and not just olfactory nerve func- tion, may
severely reduce the sense of smell [40]. This should not be forgotten when addressing
potential causes of reduced or altered olfaction.
The sensitivity of the nasal mucosa as a limiting factor
In addition to the limited access, obstacles imposed by its small dimensions and dynamics, the high
sensitivity of the mucosa in the vestibule and in the valve area is very relevant to nasal drug delivery.
Direct contact of the tip of the spray nozzle during actuation, in combination with localized
concentrated anterior drug deposition on the septum, may create mechanical irritation and injury to
the mucosa resulting in nosebleeds and crusting, and potentially erosions or perforation [41]
high-speed impaction and low temperature of some pressurized devices may cause unpleasant
sensations reducing patient acceptance and compliance.
The role of the high sensitivity of the nasal mucosa as a natural nasal defense is too often
neglected when the potential of nasal drug delivery is discussed, in particular when results from
animal studies, cast studies, and computer fluid dynamics (CFD) are evaluated. Exposure to
chemicals, gases, particles, temperature and pressure changes, as well as direct tactile stimuli, may
cause irritation, secretion, tearing, itching, sneezing, and severe pain [39]. Sensory, motor, and
parasympathetic nerves are involved in a number of nasal reflexes with relevance to nasal
drug delivery [4]. Such sensory inputs and related reflexes are suppressed by the anesthesia
and/or sedation often applied to laboratory animals, potentially limiting the clinical predictive
value of such studies. Further, the lack of sensory feedback and absence of interaction between
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:829
YMER || ISSN : 0044-0477
http://ymerdigital.com
the device and human sub- jects/patients are important limitations of in vitro testing of airflow and
deposition patterns in nasal casts and in CFD simulation of deposition. Consequently,
deposition studies in nasal casts and CFD simulation of airflow and deposition are of value, but
their predictive value for the clinical setting are all too often overestimated.
Methods of Delivery
Nasal drug delivery fluid dynamics is a rapidly growing area of intense research investigation.
This high level of interest is directly tied to a number of commercial products, each with variable
published experimental support. Studies on delivery methods have focused on the state of the paranasal sinuses (non-operated vs. post-surgical) and the device dynamics (device, techniques, volume,
position).
Nasal Surgery is a Prerequisite for Effective Sinus
Topical Drug Delivery
It is well established that the delivery of topical solution to the non-operated sinuses is very
limited [6•]. Pressurized nasal spray provide only nasal cavity penetration at best, and squeeze
bottle and Neti pot irrigation only provide some maxillary sinus and ethmoid sinus penetration
[6•]. The frontal and sphenoid sinuses are essentially not accessible prior to surgery [6•].
Olson evaluated three methods of nasal irrigation in healthy non-operated individuals, and
found distribution in the nasal cavity but poor distribution in the sinuses with all techniques [7].
With CRS, mucosal inflammation and edema further limit the penetration of nasal irrigation or
sprays [8]. Grobler et al. showed that an ostial size of greater than 3.95 mm is required to see
penetration into the maxillary sinus [9].
Endoscopic sinus surgery allows for more effective delivery of topical drugs, although the
degree to which access is increased depends on the extent and technique of
even wider variability in the size of ‘‘post-surgical’’ sinus openings exists. This heterogeneity
creates a confounding variable in determining the effectiveness of topical drug delivery in
post-surgical sinus cavities. In Harvey’s cadaveric study, delivery to the sinuses improved
after
Devices to Deliver Saline
There are a number of devices on the market for topical saline delivery into the nose and
paranasal sinuses. They vary mainly in the volume and pressure of delivery (Table 1).
Regardless of device or technique, penetration into the sinuses is very limited in non-operated
sinuses [6•,
8, 9]. Two common high-volume techniques for delivery of nasal saline are the squeeze bottle (high
pressure) and the Neti pot (low pressure). Large volume systems have been shown to have the best
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:830
YMER || ISSN : 0044-0477
http://ymerdigital.com
efficacy in post-ESS cavities, with large volume high pressure devices being superior [6•, 9– 12].
Low volume devices, such as the pump spray (high pressure) or the nebulizer (low pressure),
poorly penetrate the sinuses even after ESS [6•, 12]. Less than 50 % of most low volume devices
reach the middle meatus [13]. Low volume systems should be considered a nasal cavity
treatment because both pre- and post-surgical penetration into the sinuses is extremely poor.
Drug Delivery Devices
Nasal pump sprays are a popular option for topical drug delivery because of their ease of
use, and many different formulations are available in this format. The main factors associated
with particle penetration include the size of the sinus ostia, the size of the particle, and the flow rate
of the aerosol [14, 15]. Particles [10 lm in size usually do not pass the nasal cavity, and
particles \5 lm in size are needed to enter into the lungs. Hyoet al. theorized that ideal
particle size for maxillary sinus penetration is between 3 and 10 lm, and further work
by Saijo et al. demonstrated that smaller particle size (5.63 vs. 16.37 lm),
45 insertion angle (vs. 30 insertional angle), and higher flow rate improved maxillary sinus
penetration [14, 16].
Typical nasal pump sprays generate droplets of 50–100 lm in diameter size, and deliver
70–150 ll of drug per puff, at standard velocities of 7.5–20 L/min [5]. A large fraction of the spray
is deposited in the anterior nasal cavity without any significant penetration into the paranasal
Patient Positioning for Drug Delivery
There is no consensus on the most effective position for delivering topical drugs into the nose
and paranasal sinu- ses. Many commercial products recommend a head-down, over-the-sink, or
nose-to-ground position for nasal irriga- tion. This makes the residual runoff easy to collect and
is practical for patients. The delivery of nasal drops relative to head position has been studied [13,
22]. One study found that the ‘‘Mygind’’ and ‘‘Ragan’’ (left lateral and supine) positions were
more effective than the ‘‘Mecca’’ and
Head-back’’ positions for delivery into the middle meatus [22]. However, this has not been
supported in other studies [13, 23–26]. Head-down or ‘‘vertex-to-floor’’ position has been
suggested to lead to better frontal distribution post- ESS [27]. Positioning is more relevant
for low-pressure delivery systems. For example, when using the neti pot, the Mygind head position
allows for gravity-dependent drain- age into the contralateral nasal wall and sinuses. Positioning with high-pressure delivery systems may have less clinical importance [5].
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:831
YMER || ISSN : 0044-0477
http://ymerdigital.com
Drugs and Compounds
Saline
Saline irrigations and sprays are the most commonly used intervention for rhinitis and
rhinosinusitis. Nasal saline has its roots in homeopathic medicine. Nasal washing is an ancient
Ayurvedic technique known as ‘‘Jala neti’’, which means nasal cleansing in Sanskrit. Today,
it is often used as an adjunctive treatment for chronic rhinos- inusitis. Its use has been
advocated both before and fol- lowing sinus surgery, and in the latter case to thoroughly cleanse
the Nasal passages and promote mucosal healing. Much of the support for this intervention
has been anecdotal; however, recent literature has provided evidence to support the use of
nasal saline for symptom improvement [28••].
Targeted nasal delivery
For most purposes, a broad distribution of the drug on the mucosal surfaces appears desirable for
drugs intended for local action or systemic absorption and for vaccines [3]. However, in
chronic sinusitis and nasal polyposis, targeted delivery to the middle and superior meatuses
where the sinus openings are, and where the polyps originate, appears desirable [42, 43]. Another
exception may be drugs intended for “nose-to-brain” delivery, where more targeted delivery to
the upper parts of the nose housing the olfactory nerves has been believed to be essential.
However, recent animal data suggest that some degree of transport can also occur along the
branches of the first and second divisions of the trigeminal nerve innervating most of the mucosa
at and beyond the nasal valve [44]. This suggests that, in contrast to the prevailing opinion, a
combination of targeted delivery to the olfactory region and a broad distribution to the mu- cosa
innervated by the trigeminal nerve may be optimal for N2B delivery. Targeted delivery will be
discussed in more detail below.
Nasal drug delivery devices
comprehensive review from 1998 and will only be briefly described here, with focus instead on
technological features directly impacting particle deposition and on new and emerging
technologies and devices. Liquid formulations currently completely dominate the nasal drug
market, but nasal powder formulations and devices do exist, and more are in development. Table
1 provides an overview of the main types of liquid and powder delivery devices, their key
characteristics, and examples of some key marketed nasal products and emerging devices and
drug–device combina- tion products in clinical development (Table 1).
Devices for liquid formulations
The liquid nasal formulations are mainly aqueous solutions, but suspensions and emulsions can
also be delivered. Liquid formulations are considered convenient particularly for top- ical
indications where humidification counteracts the dry- ness and crusting often accompanying
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:832
YMER || ISSN : 0044-0477
http://ymerdigital.com
chronic nasal diseases [3]. In traditional spray pump systems, preserva- tives are typically
required to maintain microbiological sta- bility in liquid formulations. Studies in tissue cultures
and animals have suggested that preservatives, like benzalko- nium chloride in particular,
could cause irritation and re- duced ciliary movement. However, more recent human studies
based on long-term and extensive clinical use have concluded that the use of benzalkonium
chloride is safe and well tolerated for chronic use [45]. For some liquid formu- lations, in particular
peptides and proteins, limited stability of dissolved drug may represent a challenge [46].
Drops delivered with pipette
Drops and vapor delivery are probably the oldest forms of nasal delivery. Dripping breast milk has
been used to treat nasal congestion in infants, vapors of menthol or similar substances were
used to wake people that have fainted, and both drops and vapors still exist on the market (e.g.,
www.vicks.com). Drops were originally administered by sucking liquid into a glass dropper,
inserting the dropper into the nostril with an extended neck before squeezing the rubber top to emit
the drops. For multi-use purposes, drops have to a large extent been replaced by metered-dose spray
pumps, but inexpensive single-dose pipettes produced by “blow-fill-seal” technique are still
common for OTC prod- ucts like decongestants and saline. An advantage is that preservatives
are not required. In addition, due to inadequate clinical efficacy of spray pumps in patients with
nasal pol- yps, a nasal drop formulation of fluticasone in single-dose pipettes was introduced in the
EU for the treatment of nasal polyps. The rationale for this form of delivery is to improve drug
deposition to the middle meatus where the polyps emerge [47, 48]. some, their popularity is
limited by the need for head-down body positions and/or extreme neck extension required for the
desired gravity-driven deposition of drops [43, 49]. Compliance is often poor as patients
with rhinosinusitis often experience increased headache and discomfort in head-down positions.
Delivery of liquid with rhinyle catheter and squirt tube
A simple way for a physician or trained assistant to deposit drug in the nose is to insert the tip
of a fine catheter or micropipette to the desired area under visual control and squirt the liquid
into the desired location. This is often used in animal studies where the animals are anesthetized
or sedated, but can also be done in humans even without local anesthetics if care is taken to
minimize contact with the sensitive mucosal membranes [50]. This method is, howev- er, not
suitable for self-administration. Harris et al. [51] described a variant of catheter delivery where
0.2 ml of a liquid desmopressin formulation is filled into a thin plastic tube with a dropper. One
end of the tube is positioned in the nostril, and the drug is administered into the nose as drops or as
a “liquid jet” by blowing through the other end of the thin tube by the mouth [51]. Despite a rather
cumbersome pro- cedure with considerable risk of variability in the dosing, desmopressin is
still marketed in some countries with this rhinyle catheter alongside a nasal spray and a tablet
for treatment of primary nocturnal enuresis, Von Willebrand disease, and diabetes insipidus.
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:833
YMER || ISSN : 0044-0477
http://ymerdigital.com
Squeeze bottles
Squeeze bottles are mainly used to deliver some over-the- counter (OTC) products like topical
decongestants. By squeezing a partly air-filled plastic bottle, the drug is atom- ized when delivered
from a jet outlet. The dose and particle size vary with the force applied, and when the pressure is
released, nasal secretion and microorganisms may be sucked into the bottle. Squeeze bottles are
not recommended for children [3].
Metered-dose spray pumps
Metered spray pumps have, since they were introduced some four decades ago, dominated the
nasal drug delivery market (Table 1). The pumps typically deliver 100 μl (25–200 μl) per spray, and
they offer high reproducibility of the emitted dose and plume geometry in in-vitro tests. The particle
size and plume geometry can vary within certain limits and depend on the properties of the pump,
the formu- lation, the orifice of the actuator, and the force applied [3]. Traditional spray pumps
replace the emitted liquid with air, and preservatives are therefore required to prevent
contamination. However, driven by the studies suggesting possible negative effects of
preservatives, pump manufac- turers have developed different spray systems that avoid the need
for preservatives. These systems use a collapsible bag, a movable piston, or a compressed gas to
compensate for the emitted liquid volume [3] (www.aptar.com and www.rexam.- com). The
solutions with a collapsible bag and a movable piston compensating for the emitted liquid
volume offer the additional advantage that they can be emitted upside down, without the risk of
sucking air into the dip tube and compro- mising the subsequent spray. This may be useful for
some products where the patients are bedridden and where a head- down application is
recommended. Another method used for avoiding preservatives is that the air that replaces the
emitted liquid is filtered through an aseptic air filter. In addition, some systems have a ball valve at
the tip to prevent contamination of the liquid inside the applicator tip (www.aptar.com). These
preservative-free pump systems become more complex and expensive, and since human studies
suggest that preservatives are safe and well tolerated, the need for preservative-free systems seems
lower than previously anticipated [45]. More recently, pumps have been designed with sideactuation and introduced for delivery of fluticasone furoate for the indication of seasonal and
perennial allergic rhinitis [52]. The pump was designed with a shorter tip to avoid contact with the
sensitive mucosal surfaces. New designs to reduce the need for priming and re-priming, and pumps
incorporating pressure point fea- tures to improve the dose reproducibility and dose counters and
lock-out mechanisms for enhanced dose control and safety are available (www.rexam.com and
www.aptar.com). Importantly, the in vivo deposition and clinical performance of metered-dose
spray pumps can be enhanced for some applications by adapting the pumps to a novel
breath- powered “Bi-Directional™” delivery technology described in more detail below [13].
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:834
YMER || ISSN : 0044-0477
http://ymerdigital.com
References
1. FDA 2003. US FDA draft guidance for industry. Bioavailability and bioequivalence studies
for nasal aerosolsand nasal sprays. Bethesda. http://www.fda.gov/cder/guidance/index.htm.
Accessed July 2012.
2. Suman JD, Laube BL, Dalby R. Validity of in vitro tests on aqueous spray pumps as
surrogates for nasal deposition, absorp- tion and biologic response. J Aerosol Med. 2006;
19:510–21.
3. Vidgren MT, Kublik H. Nasal delivery systems and their effect on deposition and
absorption. Adv Drug Deliv Rev. 1998;29:157–77.
4. Sahin-Yilmaz A, Naclerio RM. Anatomy and physiology of the upper airway. Proc Am
Thorac Soc. 2011;8:31–9.
5. Cole P. Nasal respiratory function. In: The nose. St. Louis: Mosby-Year Book Inc.;
1993. p. 3–60.
6. Cole P. The mouth and the throat. In: The nose. St. Louis: Mosby- Year Book Inc.; 1993. p.
61–90.
7. Haight JS, Cole P. The site and function of the nasal valve. Laryngoscope. 1983;93:49–
55.
8. Yu S, Liu Y, Sun X, Li S. Influence of nasal structure on the distribution of airflow
in nasal cavity. Rhinology. 2008;46:137–44.
9. Cole P. The four components of the nasal valve. Am J Rhinol. 2003;17:107–10.
10. Fodil R, Brugel-Ribere L, Croce C, Sbirlea-Apiou G, Larger C, Papon JC, Delclaux C, Coste
A, Isabay D, Louis B. Inspiratory flow in the nose: a model coupling flow and vasoerectile
tissue distensibility. J Appl Physiol. 2005;98:288–95.
11. Cole P. Nasal and oral airflow resistors. Site, function, and as- sessment. Arch
Otolaryngol Head Neck Surg. 1992;118:790–3.
12. Gomes AC, Sampaio-Teixeira ACM, Trindade SHK, Trindade IEK. Nasal cavity
geometry of healthy adults assessed using acous- tic rhinometry. Rev Bras Otorrinolaringol.
2008;74(5):746–54.
13. Djupesland PG, Skretting A, Windern M, Holand T. Breath actuated device improves
delivery to target sites beyond the nasal valve. Laryngoscope. 2006;116(3):466–72.
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:835
YMER || ISSN : 0044-0477
http://ymerdigital.com
14. Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a
bidirectional powder device and a liquid spray pump. J Aerosol Med Pulm. 2012.
doi:10.1089/ jamp.2011.0924.
15. Swift DL, Proctor DF. Access of air to the respiratory tract. In: Brain DJ, Proctor DF, Reid
LM, editors. Respiratory defense mechanisms. New York: Marcel Dekker; 1977. p. 63–93.
16. Mann DG, Sasaki CT, Fukuda H, Suzuki M, Hernandez JR. Dilator naris muscle.
Ann Otol Rhinol Laryngol. 1977; 86:362–70.
17. Djupesland PG, Skatvedt O, Brogersen AK. Dichotomous phys- iological effects of
nocturnal external nasal dilation in heavy snorers: the answer to a rhinological controversy?
Am J Rhninol. 2001;15(2):95–103.
18. Hairfield WM, Warren DW, Hinton VA, Seaton DL. Inspiratory and expiratory effects of
nasal breathing. Cleft Palate J. 1987;24:183–9.
19. Mygind N, Dahl R. Anatomy, physiology and function of the nasal cavities in health
and disease. Adv Drug Deliv Rev. 1998;29:3–12.
20. Proctor DF. The mucociliary system. In: Proctor DF, Andersen I, editors. The nose: upper
airway physiology and the atmo- spheric environment. Amsterdam: Elsevier Biomedical;
1982. p. 245–78.
21. Halama AR, Decreton S, Bijloos JM, Clement PAR. Density of epithelial cells in the normal
human nose. A scanning electron microscopic study. Rhinology. 1990;28:25–32.
22. Svensson S, Olin AC, Hellgren J. Increased net water loss by oral compared to nasal
expiration in healthy subjects. Rhinology. 2006;44:74–7.
23. Andersen I, Lundqvist GR, Jensen PL, Proctor DF. Human re- sponse to controlled
levels of sulfur dioxide. Arch Environ Hlth. 1974;28:31–9.
24. Brandtzaeg P. Role of secretory antibodies in the defense against infections. Int J Med
Microbiol. 2003;293:1–13.
25. Baraniuk JN. Neural regulation of mucosal function. Pulm Phar- macol Ther. 2008;21(3):442–
8.
26. Cole P. Stability of nasal airflow. Clnin Otolaryngol. 1989;14:177–82.
27. Cole P, Haight JSJ. Posture and the nasal cycle. Ann Otol Rhinol Laryngol. 1986;95:223–7.
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:836
YMER || ISSN : 0044-0477
http://ymerdigital.com
28. Havas TE, Cole P, Gullane PJ, et al. The nasal cycle after laryngoectomy. Acta
Otolaryngo (Stockh). 1987;103:111–6.
29. Djupesland PG, Chatkin JM, Qian W, Haight JSJ. Nitric oxide in the nasal airway: a new
dimension in otolaryngology. Am J Otolaryngol. 2001;22:19–32.
30. Qian W, Sabo R, Ohm M, Haight JSJ, Fenton R. Nasal nitric oxide and the nasal cycle.
Laryngoscope. 2001;111:1603–7.
31. Jones N. The nose and paranasal sinuses physiology and anato- my. Adv Drug Deliv Rev.
2001;51:5–19.
32. Einer-Jensen N, Larsen L. Local transfer of diazepam, but not of cocaine, from the nasal
cavities to the brain arterial blood in rats. Pharmacol Toxicol. 2000;87:276–8.
33. Einer-Jensen N, Larsen L, Deprez S, Starns E, Schwartz S. Intranasal absorption of
sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain
arterial blood in male rats. Biopharm Drug Dispos. 2001;22(5):213–9.
34. Dhuria S, Hanson LR, Frey WH. Intranasal delivery to the central nervous system:
mechanisms and experimental considerations. J Pharm Sci. 2009. doi:10.1002/jps.21924.
35. Landis BN, Scheibe M, Weber C, Berger R, Brämerson A, Bende M, Nordin S, Hummel
T. Chemosensory interaction: acquired olfactory impairment is associated with decreased taste
function. J Neurol. 2010;257:1303–8.
36. Brant JG. Within reach of an end to unnecessary bitterness. Lancet. 2000;356:1371–2.
37. Feron F, Perry C, McGrath JJ, Mackay-Sim A. New techniques for biopsy and culture of
human olfactory epithelial neurons. Arch Otolaryngol Head Neck Surg. 1988;124(8):861–6.
Leopold DA, Hummel T, Schwob JE. Anterior distribution of human olfactory epithelium.
Laryngoscope. 2000;110:417–21.
39. Hummel T, Livermore A. Intranasal chemosensory function of the trigeminal nerve and
aspects of its relation to olfaction. Int Arch Occup Environ Health. 2002;75:305–13.
40. Husner A, Frasnelli J, Welge-Lussen A, Reiss G, Zahnert T, Hummel T. Loss of trigeminal
sensitivity reduces olfactory func- tion. Laryngoscope. 2006;116:1520–2.
41. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid spary in the treatment of
rhinitis: is one better than another? J Laryngol Otol. 2003;117:8843–5.
42. Laube B. Devices for aerosol delivery to treat sinusitis. J Aerosol Med. 2007;20(Suppl):5–18.
43. Aggrawal R, Cardozo A, Homer JJ. The assessment of topical nasal drug distribution.
Clin Otolaryngol. 2004;29:201–5.
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:837
YMER || ISSN : 0044-0477
http://ymerdigital.com
44. Johnson HJ, Hanson LR, Frey WH. Trigeminal pathways deliver a low molecular weight
drug from the nose to the brain and orofacial structures. Mol Pharm. 2010;7(3):884–93.
45. Marple B, Roland P, Benninger M. Safety review of benzalko- nium chloride used as
a preservative in intranasal solutions: an overview of conflicting data and opinions.
Otolaryngol Head Neck Surg. 2004;130:131–41.
46. Illum L. Nasal drug delivery: possibilities, problems and solu- tions. J Control Release.
2003;87:187–98.
47. Penttilä M, Poulsen P, Hollingworth K, Holmström M. Dose- related efficacy and
tolerability of fluticasone propionate nasal drops 400 μg once daily and twice daily in the
treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin
Exp Allergy. 2000; 30:94–102.
48. Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of fluticasone
propionate nasal drops 400 μg once daily compared with placebo for the treatment of bilateral
poly- posis in adults. Clin Exp Allergy. 2000; 30: 1460–8.
49. Merkus P, Ebbens FA, Muller B, Fokkens WJ. Influence of anatomy and head position
on intranasal drug deposition. Eur Arch Otorhinolaryngol. 2006;263:827–32.
50. Bakke B, Samdal HH, Holst J, et al. Vaccine oral spray immuni- zation may be an alternative
to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or
cellular immunity. Scan J of Immunol. 2006; 63:223–31.
51. Harris AS, Nilsson IM, Wagner ZG, Alkner U. Intranasal administration of peptides: nasal
deposition, biological re- sponse and absorption of desmopressin. J Pharm Sci. 1986;
75:1085–8.
52. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug
delivery device for fluticasone furoate as a potential step toward improved compliance.
Expert Opin Drug Deliv. 2007;4(6):689–701.
53. Kanowitz SJ, Batra PS, Citardi MJ. Topical budesonide via mucosal atomization device
in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008;
139:131–6.
54. Renteria SS, Clemens CC, Croyle MA. ∗Development of a nasal adenovirus-based vaccine:
effect of concentration and formula- tion on adenovirus stability and infectious titer during
actuation from two delivery devices. Vaccine. 2010; 28: 2137–48.
55. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal
influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA.
1999;
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:838
YMER || ISSN : 0044-0477
http://ymerdigital.com
282:137–44.
56. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza
vaccine in infants and young children. N Engl J Med.2007; 356: 685–96.
57. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and
the risk of Bell’s palsy in Swit- zerland. N Engl
VOLUME 21 : ISSUE 7 (July) - 2022
Page No:839